An analysis of the multicenter results of the Digital Mammography Imaging Screen Trial has found that digital mammography outperforms conventional screen film mammography for women under 50 who have dense breasts.
An analysis of the multicenter results of the Digital Mammography Imaging Screen Trial has found that digital mammography outperforms conventional screen film mammography for women under 50 who have dense breasts.DMIST, sponsored by the American College of Radiology Imaging Network, enrolled 49,528 women at 33 centers in the U.S. and Canada. The women underwent both digital and film mammography. Breast cancer status was determined for 42,760 women. The results from the follow-up analysis appear in the February issue of Radiology.
Researchers led by principal investigator Dr. Etta D. Pisano at the University of North of Carolina at Chapel Hill retrospectively compared results in 10 different subgroups of women:
The most recent findings confirmed the trial's original findings in favor of improved diagnostic accuracy of digital mammography over film for pre- and perimenopausal women under 50 years old with dense breasts, according to Pisano.
"This paper confirms that if you are under 50, pre- or perimenopausal, and have dense breasts, you should definitely be screened with digital rather than film," Pisano said.The results also showed a trend toward improved diagnostic accuracy of film over digital mammography for women over 65 with fatty breasts. This finding was not statistically significant, however, and further investigation is needed to determine the reason that film performed slightly better in this subgroup. For other groups evaluated, there was no significant difference.For more information from the Diagnostic Imaging archives:
Digital mammography hits mainstream use
DMIST results highlight possible downsides of digital mammography in older women
After a long haul, digital finally gains an edge
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.